Cargando…

Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study

OBJECTIVES: To investigate the presence, nature and relationship to age, sex, ethnicity and body mass index (BMI) of adverse reactions following routine cycloplegic eye drops in children. DESIGN: Prospective observational cohort study. SETTING: Ophthalmology outpatient clinic Dutch metropolitan hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: van Minderhout, Helena M, Joosse, Maurits V, Grootendorst, Diana C, Schalij-Delfos, Nicoline E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691733/
https://www.ncbi.nlm.nih.gov/pubmed/26700273
http://dx.doi.org/10.1136/bmjopen-2015-008798
_version_ 1782407184474177536
author van Minderhout, Helena M
Joosse, Maurits V
Grootendorst, Diana C
Schalij-Delfos, Nicoline E
author_facet van Minderhout, Helena M
Joosse, Maurits V
Grootendorst, Diana C
Schalij-Delfos, Nicoline E
author_sort van Minderhout, Helena M
collection PubMed
description OBJECTIVES: To investigate the presence, nature and relationship to age, sex, ethnicity and body mass index (BMI) of adverse reactions following routine cycloplegic eye drops in children. DESIGN: Prospective observational cohort study. SETTING: Ophthalmology outpatient clinic Dutch metropolitan hospital; February, March and April 2009. PARTICIPANTS: Children aged 3–14-year-old children receiving two drops of cyclopentolate 1% (C+C) or one drop of cyclopentolate 1% and one drop of tropicamide 1% (C+T). Patients were categorised by age (3–6, 7–10 and 11–14 years), sex, ethnicity and body mass index (BMI) (low, normal or high). OUTCOME MEASURES: Rate and nature of adverse reactions reported at 45 min following treatment. Crude and adjusted ORs for reporting an adverse reaction using stepwise regression analysis with BMI, age, ethnicity and sex. RESULTS: 912 of 915 eligible patients participated (99.7%). Adverse reactions were reported for C+C in 10.3% and in C+T in 4.8% (42/408 and 24/504, p=0.002), respectively. Central effects were present in 95% in C+C and in 92% in C+T. Compared to C+T, an increased risk was present in C+C (crude OR 2.3 (1.4 to 3.9), p=0.002). Forward adjustment showed BMI to be an influencing factor in treatment (OR 3.1 (1.7 to 5.6), p<0.001). In a multivariate model, a dose of cyclopentolate remained associated with adverse reactions. Analysis per BMI and regime and age category and regime, indicated associations with low BMI (OR C+C 21.4 (6.7 to 67.96), p<0.001, respectively, C+T 5.2 (2.1 to 12.8), p<0.001) and young age (OR C+C 8.1 (2.7 to 24.8), p<0.001). CONCLUSIONS: Adverse reactions were common and almost exclusively involved the central nervous system. Both presence and severity were associated with repeated instillation of cyclopentolate 1%, low BMI and young age. In specific paediatric populations, a single dose of cyclopentolate must be considered. Vital function monitoring facilities are advisable. Adjustment of guidelines is recommended.
format Online
Article
Text
id pubmed-4691733
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46917332015-12-30 Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study van Minderhout, Helena M Joosse, Maurits V Grootendorst, Diana C Schalij-Delfos, Nicoline E BMJ Open Ophthalmology OBJECTIVES: To investigate the presence, nature and relationship to age, sex, ethnicity and body mass index (BMI) of adverse reactions following routine cycloplegic eye drops in children. DESIGN: Prospective observational cohort study. SETTING: Ophthalmology outpatient clinic Dutch metropolitan hospital; February, March and April 2009. PARTICIPANTS: Children aged 3–14-year-old children receiving two drops of cyclopentolate 1% (C+C) or one drop of cyclopentolate 1% and one drop of tropicamide 1% (C+T). Patients were categorised by age (3–6, 7–10 and 11–14 years), sex, ethnicity and body mass index (BMI) (low, normal or high). OUTCOME MEASURES: Rate and nature of adverse reactions reported at 45 min following treatment. Crude and adjusted ORs for reporting an adverse reaction using stepwise regression analysis with BMI, age, ethnicity and sex. RESULTS: 912 of 915 eligible patients participated (99.7%). Adverse reactions were reported for C+C in 10.3% and in C+T in 4.8% (42/408 and 24/504, p=0.002), respectively. Central effects were present in 95% in C+C and in 92% in C+T. Compared to C+T, an increased risk was present in C+C (crude OR 2.3 (1.4 to 3.9), p=0.002). Forward adjustment showed BMI to be an influencing factor in treatment (OR 3.1 (1.7 to 5.6), p<0.001). In a multivariate model, a dose of cyclopentolate remained associated with adverse reactions. Analysis per BMI and regime and age category and regime, indicated associations with low BMI (OR C+C 21.4 (6.7 to 67.96), p<0.001, respectively, C+T 5.2 (2.1 to 12.8), p<0.001) and young age (OR C+C 8.1 (2.7 to 24.8), p<0.001). CONCLUSIONS: Adverse reactions were common and almost exclusively involved the central nervous system. Both presence and severity were associated with repeated instillation of cyclopentolate 1%, low BMI and young age. In specific paediatric populations, a single dose of cyclopentolate must be considered. Vital function monitoring facilities are advisable. Adjustment of guidelines is recommended. BMJ Publishing Group 2015-12-22 /pmc/articles/PMC4691733/ /pubmed/26700273 http://dx.doi.org/10.1136/bmjopen-2015-008798 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Ophthalmology
van Minderhout, Helena M
Joosse, Maurits V
Grootendorst, Diana C
Schalij-Delfos, Nicoline E
Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study
title Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study
title_full Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study
title_fullStr Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study
title_full_unstemmed Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study
title_short Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study
title_sort adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study
topic Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691733/
https://www.ncbi.nlm.nih.gov/pubmed/26700273
http://dx.doi.org/10.1136/bmjopen-2015-008798
work_keys_str_mv AT vanminderhouthelenam adversereactionsfollowingroutineanticholinergiceyedropsinapaediatricpopulationanobservationalcohortstudy
AT joossemauritsv adversereactionsfollowingroutineanticholinergiceyedropsinapaediatricpopulationanobservationalcohortstudy
AT grootendorstdianac adversereactionsfollowingroutineanticholinergiceyedropsinapaediatricpopulationanobservationalcohortstudy
AT schalijdelfosnicolinee adversereactionsfollowingroutineanticholinergiceyedropsinapaediatricpopulationanobservationalcohortstudy